Ultragenyx agrees to sell rare pediatric disease priority review voucher for $210 million
RARE•Ultragenyx entered a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $210 million. The proceeds are expected to fund pipeline development and support the company’s profitability plans.
1. Voucher sale agreement
The voucher was awarded when the FDA cleared GENGLYCOS (DTX401) for glycogen storage disease type Ia. The sale’s closing depends on customary conditions, including expiration of the Hart-Scott-Rodino waiting period.
